摘要
目的:观察复方苦参注射液联合经导管动脉化疗栓塞(transarterial chemoembolization,TACE)治疗肝癌的临床疗效、生存率及不良反应的情况。方法:选2021年3月—2024年3月我院收治住院的中晚期肝癌患者102例,随机分为对照组和观察组各51例。对照组给予TACE治疗(奥沙利铂100 mg+吡柔比星30 mg),观察组在对照组的基础上给予复方苦参注射液(20 mL)。观察并对比两组患者治疗前后的临床疗效、肿瘤标志物、生存率、肝功能、血常规及不良反应发生情况。结果:治疗后,观察组临床总缓解率为70.59%(36/51)比对照组47.06%(24/51)明显改善(P<0.05)。治疗后,两组患者的肿瘤标志物水平较治疗前均明显降低(P<0.05),且观察组降低幅度优于对照组(P<0.05)。两组患者的血常规血小板、白细胞计数水平较治疗前均有所降低(P<0.05),但观察组降低幅度较少,两组对比具有统计学差异(P<0.05)。治疗后,两组患者的半年生存率对比无统计学意义(P>0.05),但是一年生存率,观察组明显优于对照组(P<0.05)。在不良反应发生方面,发热及骨髓抑制方面对比无统计学意义(P>0.05),但疼痛、恶心呕吐方面,观察组明显优于对照组(P<0.05)。结论:复方苦参注射液联合TACE治疗肝癌临床疗效显著,能有限缓解肝功能损伤,改善造血相关指标(红细胞、血红蛋白、血小板及白细胞)的水平,提升患者的生存率,降低不良反应发生率。
Objective:To observe the clinical efficacy,survival rate and adverse reactions of compound Kushen injection combined with TACE in the treatment of liver cancer.Methods:102 patients with advanced liver cancer admitted to our hospital from March 2021 to March 2024 were randomly divided into control group and observation group with 51 cases in each group.The control group was given TACE(oxaliplatin 100 mg+pirarubicin 30 mg),and the observation group was given compound Kushen injection(20 mL)on the basis of the control group.To observe and compare the clinical efficacy,tumor markers,survival rate,liver function,blood routine and adverse reactions of the two groups before and after treatment.Results:After treatment,the total clinical remission rate in the observation group was 70.59%(36/51),which was significantly improved compared with that in the control group(47.06%,24/51)(P<0.05).After treatment,the levels of tumor markers in the two groups were significantly lower than those before treatment(P<0.05),and the reduction in the observation group was better than that in the control group(P<0.05).The platelet and white blood cell counts of patients in the two groups decreased compared with those before treatment(P<0.05),but the decrease in the observation group was less,and there was a statistical difference between the two groups(P<0.05).After treatment,there was no significant difference in the half-year survival rate between the two groups(P>0.05),but the one-year survival rate in the observation group was significantly better than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between fever and bone marrow suppression(P>0.05),but the pain,nausea and vomiting in the observation group were significantly better than those in the control group(P<0.05).Conclusion:Compound Kushen injection combined with TACE has a significant clinical effect on liver cancer,which can alleviate liver function damage,improve platelet and leukocyte levels,improve the survival rate of patients and reduce the incidence of adverse reactions.
作者
祖恩霞
刘占伟
ZU Enxia;LIU Zhanwei(Department of Minimally Invasive Interventions,Tumour Hospital,Huainan Dongfang Hospital Group,Anhui Huainan 232000,China)
出处
《现代肿瘤医学》
2025年第9期1573-1578,共6页
Journal of Modern Oncology
关键词
肝癌
复方苦参注射液
TACE
临床疗效
不良反应
liver cancer
compound Kushen injection
TACE
clinical efficacy
adverse effect
